Hikma Pharmaceuticals PLC the multinational pharmaceutical company, has launched Cisplatin Injection, 1mg/mL in 50mL and 100mL vials, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc.

Cisplatin Injection is indicated as therapy to be employed as follows:

• Metastatic Testicular Tumors

In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.

• Metastatic Ovarian Tumors

In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin Injection and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy.

• Advanced Bladder Cancer

Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

According to IQVIA, US sales of Cisplatin Injection, 1mg/mL in 50mL and 100mL, were approximately $5 million in the 12 months ending May 2019.